Stephen Hanauer to Biosimilar Pharmaceuticals
This is a "connection" page, showing publications Stephen Hanauer has written about Biosimilar Pharmaceuticals.
Connection Strength
1.955
-
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 Feb; 41(2):509-533.
Score: 0.941
-
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 10; 6(10):816-825.
Score: 0.799
-
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728.
Score: 0.214